ImpediMed Ltd (IPD) - Financial and Strategic SWOT Analysis Review

November 2021 | 40 pages | ID: IFB1A64A296EN
GlobalData

Abstracts

ImpediMed Ltd (IPD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImpediMed Ltd (ImpediMed) is a manufacturer of bioimpedance devices with a focus on medical applications in the fluid status domain. It designs, manufactures and sells bioimpedance spectroscopy (BIS) devices for assessing lymphoedema and body composition. It harnesses BIS technologies in the non-invasive clinical assessment and monitoring of fluid status. Its major products include SOZO, SFB7, ImpediVET, L-Dex U400 and DF50. Its products are based on BIS and bioimpedance analysis platform technologies and they obtain readings from a wide frequency range to improve the accuracy of bioimpedance analysis. The company sells its products through distributors in Australia, Europe, and the US. ImpediMed is headquartered in Brisbane, Queensland, Australia.

ImpediMed Ltd Key Recent Developments

Aug 24,2021: ImpediMed : Receipt of $1.8 million R&D tax incentive refund
Feb 24,2021: ImpediMed’s COVID-19 US CARES Act Loan forgiven
Jan 07,2021: ImpediMed : Option exercise and preliminary quarterly cash flow results
Aug 11,2020: ImpediMed announces appointment of chief financial officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ImpediMed Ltd - Key Facts
ImpediMed Ltd - Key Employees
ImpediMed Ltd - Key Employee Biographies
ImpediMed Ltd - Major Products and Services
ImpediMed Ltd - History
ImpediMed Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
ImpediMed Ltd - Business Description
Business Segment: Legacy
Performance
Business Segment: Other
Performance
Business Segment: SOZO
Performance
Geographical Segment: Australia / Rest of world
Performance
Geographical Segment: North America
Performance
R&D Overview
ImpediMed Ltd - Corporate Strategy
ImpediMed Ltd - SWOT Analysis
SWOT Analysis - Overview
ImpediMed Ltd - Strengths
ImpediMed Ltd - Weaknesses
ImpediMed Ltd - Opportunities
ImpediMed Ltd - Threats
ImpediMed Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ImpediMed Ltd, Medical Equipment, Deals By Year, 2015 to YTD 2021
ImpediMed Ltd, Medical Equipment, Deals By Type, 2015 to YTD 2021
ImpediMed Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 24, 2021: ImpediMed : Receipt of $1.8 million R&D tax incentive refund
Feb 24, 2021: ImpediMed’s COVID-19 US CARES Act Loan forgiven
Jan 07, 2021: ImpediMed : Option exercise and preliminary quarterly cash flow results
Aug 11, 2020: ImpediMed announces appointment of chief financial officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ImpediMed Ltd, Key Facts
ImpediMed Ltd, Key Employees
ImpediMed Ltd, Key Employee Biographies
ImpediMed Ltd, Major Products and Services
ImpediMed Ltd, History
ImpediMed Ltd, Other Locations
ImpediMed Ltd, Subsidiaries
ImpediMed Ltd, Key Competitors
ImpediMed Ltd, Ratios based on current share price
ImpediMed Ltd, Annual Ratios
ImpediMed Ltd, Annual Ratios (Cont...1)
ImpediMed Ltd, Annual Ratios (Cont...2)
ImpediMed Ltd, Interim Ratios
ImpediMed Ltd, Medical Equipment, Deals By Year, 2015 to YTD 2021
ImpediMed Ltd, Medical Equipment, Deals By Type, 2015 to YTD 2021
ImpediMed Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ImpediMed Ltd, Performance Chart (2017 - 2021)
ImpediMed Ltd, Ratio Charts
ImpediMed Ltd, Medical Equipment, Deals By Year, 2015 to YTD 2021
ImpediMed Ltd, Medical Equipment, Deals by Type, 2015 to YTD 2021